985 related articles for article (PubMed ID: 29182709)
1. The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.
de Mauléon A; Soto M; Kiyasova V; Delrieu J; Guignot I; Galtier S; Lilamand M; Cantet C; Lala F; Sastre N; Andrieu S; Pueyo M; Ousset PJ; Vellas B
J Prev Alzheimers Dis; 2017; 4(3):183-193. PubMed ID: 29182709
[TBL] [Abstract][Full Text] [Related]
2. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.
Ellis KA; Bush AI; Darby D; De Fazio D; Foster J; Hudson P; Lautenschlager NT; Lenzo N; Martins RN; Maruff P; Masters C; Milner A; Pike K; Rowe C; Savage G; Szoeke C; Taddei K; Villemagne V; Woodward M; Ames D;
Int Psychogeriatr; 2009 Aug; 21(4):672-87. PubMed ID: 19470201
[TBL] [Abstract][Full Text] [Related]
3. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
[TBL] [Abstract][Full Text] [Related]
4. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
[TBL] [Abstract][Full Text] [Related]
5. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
6. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
8. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve.
Querbes O; Aubry F; Pariente J; Lotterie JA; Démonet JF; Duret V; Puel M; Berry I; Fort JC; Celsis P;
Brain; 2009 Aug; 132(Pt 8):2036-47. PubMed ID: 19439419
[TBL] [Abstract][Full Text] [Related]
9. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
10. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
11. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.
Petersen RC; Smith GE; Ivnik RJ; Tangalos EG; Schaid DJ; Thibodeau SN; Kokmen E; Waring SC; Kurland LT
JAMA; 1995 Apr; 273(16):1274-8. PubMed ID: 7646655
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort.
Runtti H; Mattila J; van Gils M; Koikkalainen J; Soininen H; Lötjönen J;
J Alzheimers Dis; 2014; 39(1):49-61. PubMed ID: 24121959
[TBL] [Abstract][Full Text] [Related]
14. The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results.
Aalten P; Ramakers IH; Biessels GJ; de Deyn PP; Koek HL; OldeRikkert MG; Oleksik AM; Richard E; Smits LL; van Swieten JC; Teune LK; van der Lugt A; Barkhof F; Teunissen CE; Rozendaal N; Verhey FR; van der Flier WM
BMC Neurol; 2014 Dec; 14():254. PubMed ID: 25551191
[TBL] [Abstract][Full Text] [Related]
15. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
16. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
17. Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.
Hochstetler H; Trzepacz PT; Wang S; Yu P; Case M; Henley DB; Degenhardt E; Leoutsakos JM; Lyketsos CG
J Alzheimers Dis; 2016; 50(1):271-82. PubMed ID: 26639960
[TBL] [Abstract][Full Text] [Related]
18. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
